Accolade Inc. (ACCD) News
Filter ACCD News Items
ACCD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACCD News Highlights
- For ACCD, its 30 day story count is now at 3.
- Over the past 13 days, the trend for ACCD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- PRE, DEC and SA are the most mentioned tickers in articles about ACCD.
Latest ACCD News From Around the Web
Below are the latest news stories about ACCOLADE INC that investors may wish to consider to help them evaluate ACCD as an investment opportunity.
Market Participants Recognise Accolade, Inc.'s (NASDAQ:ACCD) Revenues Pushing Shares 30% HigherAccolade, Inc. ( NASDAQ:ACCD ) shareholders are no doubt pleased to see that the share price has bounced 30% in the... |
Accolade to Announce Fiscal Third Quarter 2024 Financial ResultsSEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal third quarter 2024 financial results on Monday, January 8, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/registe |
Is Accolade (ACCD) Stock Outpacing Its Business Services Peers This Year?Here is how Accolade (ACCD) and Adecco SA (AHEXY) have performed compared to their sector so far this year. |
Accolade To Present at Piper Sandler 35th Annual Healthcare ConferenceSEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York on Wednesday, November 29, 2023 at 10:00 am ET. A webcast of the company’s fireside chat will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that prov |
Accolade Announces Repurchase of $76.5 Million of 0.50% Convertible Senior Notes Due 2026SEATTLE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it has entered into separate, privately negotiated transactions with certain holders of its outstanding 0.50% Convertible Senior Notes due 2026 (the “Notes”) to repurchase (the “Repurchases”) approximately $76.5 million aggregate principal amount of the Notes for an aggregate cash repurchase price of approximately $65.8 million. “We are strategically improving our net cash position and strengthening our |
Accolade To Present at Stephens Annual Investment ConferenceSEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Stephens Annual Investment Conference in Nashville on Wednesday, November 15, 2023 at 11:00am CT. A webcast of the company’s fireside chat will be available at ir.accolade.com and a replay will be available for 90 days.About Accolade, Inc.Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides million |
Accolade Named to 2023 Deloitte Technology Fast 500™Accolade today announced it has been named to the Deloitte Technology Fast 500™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year. Accolade grew 227% during this period. |
Down -31.39% in 4 Weeks, Here's Why Accolade (ACCD) Looks Ripe for a TurnaroundAccolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Here's Why Accolade (ACCD) is Poised for a Turnaround After Losing -36.43% in 4 WeeksAccolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
GLP-1 Coverage in Employer Plans Could Nearly Double in 2024Accolade (Nasdaq: ACCD) announced today findings from an employer survey on sentiment and adoption of GLP-1 medications. A key finding: while 81% of human resource (HR) decision-makers feel that their employees would be interested, only 25% cover GLP-1s today. |